Treatment Updates for Acute Myeloid Leukemia
Thursday, December 14, 2017
6 PM EST / 5 PM CDT
Statement of Need/Activity Purpose:
For many years the overall treatment approach for acute myeloid leukemia (AML) has remained unchanged. However, in 2017 three new drug products have been approved by the FDA for specific cohorts of patients with AML: midostaurin for FLT3+ patients, enasidenib - a first in class agent for patients with IDH2 mutation, and liposome-encapsulated daunorubicin with cytarabine for t-AML and AML with MDS related changes. Furthermore, gemtuzamab-ozogamicin was brought back to the market. Available published clinical data and adverse event profiles will be reviewed. After reviewing the assigned materials, participants will be able to recommend appropriate utilization of these agents as well as manage potential adverse drug events.
- Describe the mechanism of action and potential adverse events of the novel oral chemotherapeutic agents, midostaurin and enasidenib.
- Explain the rationale and supporting evidence for the use of liposomal daunorubicin and cytarabine.
- Summarize the literature supporting the re-emergence of gemtuzumab-ozogamicin.
Amber B. Clemmons, BCOP PharmD
Clinical Assistant Professor
University of Georgia College of Pharmacy
Amber Clemmons graduated from the University Of Michigan School Of Pharmacy and subsequently completed a PGY1 residency at MCG Health/UGA College of Pharmacy and a PGY2 Oncology residency at UNC in Chapel Hill, NC. She currently works as Clinical Associate Professor at the University Of Georgia College Of Pharmacy in Augusta, GA, and actively practices as a clinical pharmacist at the AU Medical Center / Georgia Cancer Center in bone marrow transplant / hematology. She is board certified (BCOP) and is an active member of both HOPA and the ASBMT Pharmacy SIG.
Disclosure: Member: ASBMT Pharmacy Special Interest Group; Author: JOPP, JADPRO Anna’s of Pharmacotherapy, Pharmacotherapy, J Community Supportive Oncology; Academia, University of Georgia College of Pharmacy, Inpatient BMT, AU Medical Center
This activity is intended for Hematology/oncology pharmacists. This activity has been approved for 1.00 contact hours (.10CEUs) under the ACPE universal activity number 0465-0000-17-088-L04-P.
HOPA Member ‒ $20
Nonmember ‒ $40
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and post-test.